Vaccination to modulate atherosclerosis

References

• Witztum, J. L., and A. H. Lichtman. 2014. The influence of innate and adaptive immune responses on atherosclerosis. Annu. Rev. Pathol. 9: 73–102
   PubMed Web of Science ®Google Scholar
• Ait-Oufella, H., A. P. Sage, Z. Mallat, and A. Tedgui. 2014. Adaptive (T and B cells) immunity and control by dendritic cells in atherosclerosis. Circ. Res. 114: 1640–1660
   PubMed Web of Science ®Google Scholar
• Lichtman, A. H., C. J. Binder, S. Tsimikas, and J. L. Witztum. 2013. Adaptive immunity in atherogenesis: new insights and therapeutic approaches. J. Clin. Invest. 123: 27–36
   PubMed Web of Science ®Google Scholar
• Hansson, G. K., and A. Hermansson. 2011. The immune system in atherosclerosis. Nat. Immunol. 12: 204–212
   PubMed Web of Science ®Google Scholar
• Libby, P., P. M. Ridker, and G. K. Hansson. 2011. Progress and challenges in translating the biology of atherosclerosis. Nature. 473: 317–325
   PubMed Web of Science ®Google Scholar
• Tse, K., H. Tse, J. Sidney, et al. 2013. T cells in atherosclerosis. Int. Immunol. 25: 615–622
   PubMed Web of Science ®Google Scholar
• Koltsova, E. K., and K. Ley. 2011. How dendritic cells shape atherosclerosis. Trends Immunol. 32: 540–547
   PubMed Web of Science ®Google Scholar
• Ley, K., Y. I. Miller, and C. C. Hedrick. 2011. Monocyte and macrophage dynamics during atherogenesis. Arterioscler. Thromb. Vasc. Biol. 31: 1506–1516
   PubMed Web of Science ®Google Scholar
• Koltsova, E. K., C. C. Hedrick, and K. Ley. 2013. Myeloid cells in atherosclerosis: a delicate balance of anti-inflammatory and proinflammatory mechanisms. Curr. Opin. Lipidol. 24: 371–380
   PubMed Web of Science ®Google Scholar
• Andersson, J., P. Libby, and G. K. Hansson. 2010. Adaptive immunity and atherosclerosis. Clin. Immunol. 134: 33–46
   PubMed Web of Science ®Google Scholar
• Ketelhuth, D. F., and G. K. Hansson. 2011. Cellular immunity, low-density lipoprotein and atherosclerosis: break of tolerance in the artery wall. Thromb. Haemost. 106: 779–786
   PubMedGoogle Scholar
• Shimada, K. 2009. Immune system and atherosclerotic disease: heterogeneity of leukocyte subsets participating in the pathogenesis of atherosclerosis. Circ. J. 73: 994–1001
   PubMed Web of Science ®Google Scholar
• Steinberg, D., and J. L. Witztum. 2010. Oxidized low-density lipoprotein and atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 30: 2311–2316
   PubMed Web of Science ®Google Scholar
• Fredrikson, G. N., B. Hedblad, G. Berglund, et al. 2003. Identification of immune responses against aldehyde-modified peptide sequences in apoB associated with cardiovascular disease. Arterioscler. Thromb. Vasc. Biol. 23: 872–878
   PubMed Web of Science ®Google Scholar
• Nilsson, J., G. N. Fredrikson, H. Bjorkbacka, et al. 2009. Vaccines modulating lipoprotein autoimmunity as a possible future therapy for cardiovascular disease. J. Intern. Med. 266: 221–231
   PubMed Web of Science ®Google Scholar
• Wick, G., B. Jakic, M. Buszko, et al. 2014. The role of heat shock proteins in atherosclerosis. Nat. Rev. Cardiol. 11: 516–529
   PubMed Web of Science ®Google Scholar
• Fifth Joint Task Force of the European Society of, C., E. European Association of, I. European Association of Percutaneous Cardiovascular, A. European Heart Rhythm, A. Heart Failure, P. European Association for Cardiovascular, Rehabilitation, S. European Atherosclerosis, M. International Society of Behavioural, O. European Stroke, H. European Society of, D. European Association for the Study of, M. European Society of General Practice/Family, E. International Diabetes Federation, and N. European Heart. 2012. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012): the Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur. J. Prev. Cardiol. 19: 585–667
   Google Scholar
• Grundtman, C., S. B. Kreutmayer, G. Almanzar, et al. 2011. Heat shock protein 60 and immune inflammatory responses in atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 31: 960–968
   Google Scholar
• Gounopoulos, P., E. Merki, L. F. Hansen, et al. 2007. Antibodies to oxidized low density lipoprotein: epidemiological studies and potential clinical applications in cardiovascular disease. Minerva Cardioangiol. 55: 821–837
   Google Scholar
• Ravandi, A., S. M. Boekholdt, Z. Mallat, et al. 2011. Relationship of IgG and IgM autoantibodies and immune complexes to oxidized LDL with markers of oxidation and inflammation and cardiovascular events: results from the EPIC-Norfolk Study. J. Lipid Res. 52: 1829–1836
   PubMed Web of Science ®Google Scholar
• Song, L., C. Leung, and C. Schindler. 2001. Lymphocytes are important in early atherosclerosis. J. Clin. Invest. 108: 251–259
   PubMed Web of Science ®Google Scholar
• Zhou, X., A. Nicoletti, R. Elhage, and G. K. Hansson. 2000. Transfer of CD4(+) T cells aggravates atherosclerosis in immunodeficient apolipoprotein E knockout mice. Circulation 102: 2919–2922
   PubMed Web of Science ®Google Scholar
• Kahlenberg, J. M., and M. J. Kaplan. 2013. Mechanisms of premature atherosclerosis in rheumatoid arthritis and lupus. Annu. Rev. Med. 64: 249–263
   PubMed Web of Science ®Google Scholar
• Karvonen, J., M. Paivansalo, Y. A. Kesaniemi, and S. Horkko. 2003. Immunoglobulin M type of autoantibodies to oxidized low-density lipoprotein has an inverse relation to carotid artery atherosclerosis. Circulation 108: 2107–2112
   PubMed Web of Science ®Google Scholar
• Tsimikas, S., E. S. Brilakis, R. J. Lennon, et al. 2007. Relationship of IgG and IgM autoantibodies to oxidized low density lipoprotein with coronary artery disease and cardiovascular events. J. Lipid Res. 48: 425–433
   PubMed Web of Science ®Google Scholar
• Hulthe, J., L. Bokemark, and B. Fagerberg. 2001. Antibodies to oxidized LDL in relation to intima-media thickness in carotid and femoral arteries in 58-year-old subjectively clinically healthy men. Arterioscler. Thromb. Vasc. Biol. 21: 101–107
   PubMed Web of Science ®Google Scholar
• Tsiantoulas, D., C. J. Diehl, J. L. Witztum, and C. J. Binder. 2014. B cells and humoral immunity in atherosclerosis. Circ. Res. 114: 1743–1756
   PubMed Web of Science ®Google Scholar
• Crotty, S. 2011. Follicular helper CD4 T cells (TFH). Annu. Rev. Immunol. 29: 621–663
   PubMed Web of Science ®Google Scholar
• Lewis, M. J., T. H. Malik, M. R. Ehrenstein, et al. 2009. Immunoglobulin M is required for protection against atherosclerosis in low-density lipoprotein receptor-deficient mice. Circulation 120: 417–426
   PubMed Web of Science ®Google Scholar
• Stevens, T. L., A. Bossie, V. M. Sanders, et al. 1988. Regulation of antibody isotype secretion by subsets of antigen-specific helper T cells. Nature 334: 255–258
   PubMed Web of Science ®Google Scholar
• Dotevall, A., J. Hulthe, A. Rosengren, et al. 2001. Autoantibodies against oxidized low-density lipoprotein and C-reactive protein are associated with diabetes and myocardial infarction in women. Clin. Sci. (Lond.) 101: 523–531
   Google Scholar
• Sjogren, P., G. N. Fredrikson, A. Samnegard, et al. 2008. High plasma concentrations of autoantibodies against native peptide 210 of apoB-100 are related to less coronary atherosclerosis and lower risk of myocardial infarction. Eur. Heart J. 29: 2218–2226
   PubMed Web of Science ®Google Scholar
• Uyemura, K., L. L. Demer, S. C. Castle, et al. 1996. Cross-regulatory roles of interleukin (IL)-12 and IL-10 in atherosclerosis. J. Clin. Invest. 97: 2130–2138
   PubMed Web of Science ®Google Scholar
• Frostegard, J., A. K. Ulfgren, P. Nyberg, et al. 1999. Cytokine expression in advanced human atherosclerotic plaques: dominance of pro-inflammatory (Th1) and macrophage-stimulating cytokines. Atherosclerosis 145: 33–43
   PubMed Web of Science ®Google Scholar
• Laurat, E., B. Poirier, E. Tupin, et al. 2001. In vivo downregulation of T helper cell 1 immune responses reduces atherogenesis in apolipoprotein E-knockout mice. Circulation 104: 197–202
   PubMed Web of Science ®Google Scholar
• Whitman, S. C., P. Ravisankar, H. Elam, and A. Daugherty. 2000. Exogenous interferon-gamma enhances atherosclerosis in apolipoprotein E−/− mice. Am. J. Pathol. 157: 1819–1824
   PubMed Web of Science ®Google Scholar
• Whitman, S. C., P. Ravisankar, and A. Daugherty. 2002. IFN-gamma deficiency exerts gender-specific effects on atherogenesis in apolipoprotein E−/− mice. J. Interferon. Cytokine Res. 22: 661–670
   PubMed Web of Science ®Google Scholar
• Buono, C., C. E. Come, G. Stavrakis, et al. 2003. Influence of interferon-gamma on the extent and phenotype of diet-induced atherosclerosis in the LDLR-deficient mouse. Arterioscler. Thromb. Vasc. Biol. 23: 454–460
   PubMed Web of Science ®Google Scholar
• Gupta, S., A. M. Pablo, X. Jiang, et al. 1997. IFN-gamma potentiates atherosclerosis in ApoE knock-out mice. J. Clin. Invest. 99: 2752–2761
   PubMed Web of Science ®Google Scholar
• Buono, C., C. J. Binder, G. Stavrakis, et al. 2005. T-bet deficiency reduces atherosclerosis and alters plaque antigen-specific immune responses. Proc. Natl. Acad. Sci. USA 102: 1596–1601
   Google Scholar
• Ohkura, N., Y. Kitagawa, and S. Sakaguchi. 2013. Development and maintenance of regulatory T cells. Immunity 38: 414–423
   PubMed Web of Science ®Google Scholar
• Josefowicz, S. Z., L. F. Lu, and A. Y. Rudensky. 2012. Regulatory T cells: mechanisms of differentiation and function. Annu. Rev. Immunol. 30: 531–564
   PubMed Web of Science ®Google Scholar
• Sakaguchi, S., T. Yamaguchi, T. Nomura, and M. Ono. 2008. Regulatory T cells and immune tolerance. Cell 133: 775–787
   PubMed Web of Science ®Google Scholar
• Chen, Y., V. K. Kuchroo, J. Inobe, et al. 1994. Regulatory T cell clones induced by oral tolerance: suppression of autoimmune encephalomyelitis. Science 265: 1237–1240
   PubMed Web of Science ®Google Scholar
• Groux, H., A. O'Garra, M. Bigler, et al. 1997. A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature 389: 737–742
   PubMed Web of Science ®Google Scholar
• Weiner, H. L., A. P. da Cunha, F. Quintana, and H. Wu. 2011. Oral tolerance. Immunol. Rev. 241: 241–259
   PubMed Web of Science ®Google Scholar
• Mallat, Z., A. Gojova, V. Brun, et al. 2003. Induction of a regulatory T cell type 1 response reduces the development of atherosclerosis in apolipoprotein E-knockout mice. Circulation 108: 1232–1237
   PubMed Web of Science ®Google Scholar
• Ait-Oufella, H., B. L. Salomon, S. Potteaux, et al. 2006. Natural regulatory T cells control the development of atherosclerosis in mice. Nat. Med. 12: 178–180
   PubMed Web of Science ®Google Scholar
• King, V. L., L. A. Cassis, and A. Daugherty. 2007. Interleukin-4 does not influence development of hypercholesterolemia or angiotensin II-induced atherosclerotic lesions in mice. Am. J. Pathol. 171: 2040–2047
   PubMed Web of Science ®Google Scholar
• Binder, C. J., K. Hartvigsen, M. K. Chang, et al. 2004. IL-5 links adaptive and natural immunity specific for epitopes of oxidized LDL and protects from atherosclerosis. J. Clin. Invest. 114: 427–437
   PubMed Web of Science ®Google Scholar
• Cheng, X., S. Taleb, J. Wang, et al. 2011. Inhibition of IL-17A in atherosclerosis. Atherosclerosis 215: 471–474
   PubMed Web of Science ®Google Scholar
• Madhur, M. S., S. A. Funt, L. Li, et al. 2011. Role of interleukin 17 in inflammation, atherosclerosis, and vascular function in apolipoprotein e-deficient mice. Arterioscler. Thromb. Vasc. Biol. 31: 1565–1572
   PubMed Web of Science ®Google Scholar
• Danzaki, K., Y. Matsui, M. Ikesue, et al. 2012. Interleukin-17A deficiency accelerates unstable atherosclerotic plaque formation in apolipoprotein E-deficient mice. Arterioscler. Thromb. Vasc. Biol. 32: 273–280
   PubMed Web of Science ®Google Scholar
• Smith, E., K. M. Prasad, M. Butcher, et al. 2010. Blockade of interleukin-17A results in reduced atherosclerosis in apolipoprotein E-deficient mice. Circulation 121: 1746–1755
   PubMed Web of Science ®Google Scholar
• Butcher, M. J., B. N. Gjurich, T. Phillips, and E. V. Galkina. 2012. The IL-17A/IL-17RA axis plays a proatherogenic role via the regulation of aortic myeloid cell recruitment. Circ. Res. 110: 675–687
   PubMed Web of Science ®Google Scholar
• Boyle, J. J. 1997. Association of coronary plaque rupture and atherosclerotic inflammation. J. Pathol. 181: 93–99
   PubMed Web of Science ®Google Scholar
• Kyaw, T., A. Winship, C. Tay, et al. 2013. Cytotoxic and proinflammatory CD8+ T lymphocytes promote development of vulnerable atherosclerotic plaques in apoE-deficient mice. Circulation 127: 1028–1039
   Google Scholar
• Palinski, W., M. E. Rosenfeld, S. Yla-Herttuala, et al. 1989. Low density lipoprotein undergoes oxidative modification in vivo. Proc. Natl. Acad. Sci. USA 86: 1372–1376
   PubMed Web of Science ®Google Scholar
• Yla-Herttuala, S., W. Palinski, S. W. Butler, et al. 1994. Rabbit and human atherosclerotic lesions contain IgG that recognizes epitopes of oxidized LDL. Arterioscler. Thromb. Vasc. Biol. 14: 32–40
   PubMed Web of Science ®Google Scholar
• Stemme, S., B. Faber, J. Holm, et al. 1995. T lymphocytes from human atherosclerotic plaques recognize oxidized low density lipoprotein. Proc. Natl. Acad. Sci. USA 92: 3893–3897
   PubMed Web of Science ®Google Scholar
• Palinski, W., E. Miller, and J. L. Witztum. 1995. Immunization of low density lipoprotein (LDL) receptor-deficient rabbits with homologous malondialdehyde-modified LDL reduces atherogenesis. Proc. Natl. Acad. Sci. USA 92: 821–825
   PubMed Web of Science ®Google Scholar
• Ameli, S., A. Hultgardh-Nilsson, J. Regnstrom, et al. 1996. Effect of immunization with homologous LDL and oxidized LDL on early atherosclerosis in hypercholesterolemic rabbits. Arterioscler. Thromb. Vasc. Biol. 16: 1074–1079
   PubMed Web of Science ®Google Scholar
• Freigang, S., S. Horkko, E. Miller, et al. 1998. Immunization of LDL receptor-deficient mice with homologous malondialdehyde-modified and native LDL reduces progression of atherosclerosis by mechanisms other than induction of high titers of antibodies to oxidative neoepitopes. Arterioscler. Thromb. Vasc. Biol. 18: 1972–1982
   PubMed Web of Science ®Google Scholar
• George, J.,B. Afek, H. Gilburd, et al. 1998. Hyperimmunization of apo-E-deficient mice with homologous malondialdehyde low-density lipoprotein suppresses early atherogenesis. Atherosclerosis 138: 147–152
   PubMed Web of Science ®Google Scholar
• Zhou, X., G. Caligiuri, A. Hamsten, et al. 2001. LDL immunization induces T-cell-dependent antibody formation and protection against atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 21: 108–114
   PubMed Web of Science ®Google Scholar
• van Leeuwen, M., M. J. Kemna, M. P. de Winther, et al. 2013. Passive immunization with hypochlorite-oxLDL specific antibodies reduces plaque volume in LDL receptor-deficient mice. PLoS One 8: e68039
   PubMed Web of Science ®Google Scholar
• Zhou, X., A. K. Robertson, M. Rudling, et al. 2005. Lesion development and response to immunization reveal a complex role for CD4 in atherosclerosis. Circ. Res. 96: 427–434
   PubMed Web of Science ®Google Scholar
• Habets, K. L., G. H. van Puijvelde, L. M. van Duivenvoorde, et al. 2010. Vaccination using oxidized low-density lipoprotein-pulsed dendritic cells reduces atherosclerosis in LDL receptor-deficient mice. Cardiovasc. Res. 85: 622–630
   PubMed Web of Science ®Google Scholar
• Hjerpe, C., D. Johansson, A. Hermansson, et al. 2010. Dendritic cells pulsed with malondialdehyde modified low density lipoprotein aggravate atherosclerosis in Apoe(−/−) mice. Atherosclerosis 209: 436–441
   PubMed Web of Science ®Google Scholar
• Zhou, X., A. K. Robertson, C. Hjerpe, and G. K. Hansson. 2006. Adoptive transfer of CD4+ T cells reactive to modified low-density lipoprotein aggravates atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 26: 864–870
   PubMedGoogle Scholar
• Schiopu, A., J. Bengtsson, I. Soderberg, et al. 2004. Recombinant human antibodies against aldehyde-modified apolipoprotein B-100 peptide sequences inhibit atherosclerosis. Circulation 110: 2047–2052
   PubMed Web of Science ®Google Scholar
• Fredrikson, G. N., A. Schiopu, G. Berglund, et al. 2007. Autoantibody against the amino acid sequence 661-680 in apo B-100 is associated with decreased carotid stenosis and cardiovascular events. Atherosclerosis 194: e188–e192
   PubMed Web of Science ®Google Scholar
• Fredrikson, G. N., L. Andersson, I. Soderberg, et al. 2005. Atheroprotective immunization with MDA-modified apo B-100 peptide sequences is associated with activation of Th2 specific antibody expression. Autoimmunity 38: 171–179
   PubMed Web of Science ®Google Scholar
• Fredrikson, G. N., I. Soderberg, M. Lindholm, et al. 2003. Inhibition of atherosclerosis in apoE-null mice by immunization with apoB-100 peptide sequences. Arterioscler. Thromb. Vasc. Biol. 23: 879–884
   PubMed Web of Science ®Google Scholar
• Fredrikson, G. N., H. Bjorkbacka, I. Soderberg, et al. 2008. Treatment with apo B peptide vaccines inhibits atherosclerosis in human apo B-100 transgenic mice without inducing an increase in peptide-specific antibodies. J. Intern. Med. 264: 563–570
   PubMed Web of Science ®Google Scholar
• Hermansson, A., D. F. Ketelhuth, D. Strodthoff, et al. 2010. Inhibition of T cell response to native low-density lipoprotein reduces atherosclerosis. J. Exp. Med. 207: 1081–1093
   PubMed Web of Science ®Google Scholar
• Wigren, M., D. Kolbus, P. Duner, et al. 2011. Evidence for a role of regulatory T cells in mediating the atheroprotective effect of apolipoprotein B peptide vaccine. J. Intern. Med. 269: 546–556
   PubMed Web of Science ®Google Scholar
• Khallou-Laschet, J., E. Tupin, G. Caligiuri, et al. 2006. Atheroprotective effect of adjuvants in apolipoprotein E knockout mice. Atherosclerosis 184: 330–341
   Google Scholar
• Herbin, O., H. Ait-Oufella, W. Yu, et al. 2012. Regulatory T-cell response to apolipoprotein B100-derived peptides reduces the development and progression of atherosclerosis in mice. Arterioscler. Thromb. Vasc. Biol. 32: 605–612
   PubMed Web of Science ®Google Scholar
• Pierides, C., A. Bermudez-Fajardo, G. N. Fredrikson, et al. 2013. Immune responses elicited by apoB-100-derived peptides in mice. Immunol. Res. 56: 96–108
   PubMed Web of Science ®Google Scholar
• Hermansson, A., D. K. Johansson, D. F. Ketelhuth, et al. 2011. Immunotherapy with tolerogenic apolipoprotein B-100-loaded dendritic cells attenuates atherosclerosis in hypercholesterolemic mice. Circulation 123: 1083–1091
   PubMed Web of Science ®Google Scholar
• Nilsson, J., M. Wigren, and P. K. Shah. 2013. Vaccines against atherosclerosis. Expert Rev. Vaccines 12: 311–321
   PubMed Web of Science ®Google Scholar
• Engelbertsen, D., S. Rattik, A. Knutsson, et al. 2014. Induction of T helper 2 responses against human apolipoprotein B100 does not affect atherosclerosis in ApoE−/− mice. Cardiovasc. Res. 103: 304–312
   PubMedGoogle Scholar
• Chyu, K. Y., X. Zhao, P. C. Dimayuga, et al. 2012. CD8+ T cells mediate the athero-protective effect of immunization with an ApoB-100 peptide. PLoS One 7: e30780
   PubMed Web of Science ®Google Scholar
• Alexander, J., J. Sidney, S. Southwood, et al. 1994. Development of high potency universal DR-restricted helper epitopes by modification of high affinity DR-blocking peptides. Immunity 1: 751–761
   PubMed Web of Science ®Google Scholar
• Petersen, T. R., E. Bettelli, J. Sidney, et al. 2004. Characterization of MHC- and TCR-binding residues of the myelin oligodendrocyte glycoprotein 38–51 peptide. Eur. J. Immunol. 34: 165–173
   Google Scholar
• Hansson, G. K., and P. Libby. 2006. The immune response in atherosclerosis: a double-edged sword. Nat. Rev. Immunol. 6: 508–519
   PubMed Web of Science ®Google Scholar
• Chicz, R. M., R. G. Urban, J. C. Gorga, et al. 1993. Specificity and promiscuity among naturally processed peptides bound to HLA-DR alleles. J. Exp. Med. 178: 27–47
   PubMed Web of Science ®Google Scholar
• Sidney, J., S. Southwood, C. Moore, et al. 2013. Measurement of MHC/peptide interactions by gel filtration or monoclonal antibody capture. Curr. Protoc. Immunol. 18: Unit 3. doi: 10.1002/0471142735.im1803s100
   Google Scholar
• Tse, K., A. Gonen, J. Sidney, et al. 2013. Atheroprotective vaccination with MHC-II restricted peptides from ApoB-100. Front. Immunol. 4: 493. doi: 10.3389/fimmu.2013.00493
   PubMed Web of Science ®Google Scholar
• Wick, G., G. Schett, A. Amberger, et al. 1995. Is atherosclerosis an immunologically mediated disease? Immunol. Today 16: 27–33
   PubMedGoogle Scholar
• Wick, G., and Q. Xu. 1999. Atherosclerosis – an autoimmune disease. Exp. Gerontol. 34: 559–566
   PubMedGoogle Scholar
• Perschinka, H., M. Mayr, G. Millonig, et al. 2003. Cross-reactive B-cell epitopes of microbial and human heat shock protein 60/65 in atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 23: 1060–1065
   PubMed Web of Science ®Google Scholar
• Zhu, J., A. A. Quyyumi, D. Rott, et al. 2001. Antibodies to human heat-shock protein 60 are associated with the presence and severity of coronary artery disease: evidence for an autoimmune component of atherogenesis. Circulation 103: 1071–1075
   PubMed Web of Science ®Google Scholar
• Kervinen, H., T. Huittinen, O. Vaarala, et al. 2003. Antibodies to human heat shock protein 60, hypertension and dyslipidemia. A study of joint effects on coronary risk. Atherosclerosis 169: 339–344
   PubMed Web of Science ®Google Scholar
• Xu, Q., H. Dietrich, H. J. Steiner, et al. 1992. Induction of arteriosclerosis in normocholesterolemic rabbits by immunization with heat shock protein 65. Arterioscler. Thromb. 12: 789–799
   PubMed Web of Science ®Google Scholar
• George, J., Y. Shoenfeld, A. Afek, et al. 1999. Enhanced fatty streak formation in C57BL/6J mice by immunization with heat shock protein-65. Arterioscler. Thromb. Vasc. Biol. 19: 505–510
   PubMed Web of Science ®Google Scholar
• Metzler, B., M. Mayr, H. Dietrich, et al. 1999. Inhibition of arteriosclerosis by T-cell depletion in normocholesterolemic rabbits immunized with heat shock protein 65. Arterioscler. Thromb. Vasc. Biol. 19: 1905–1911
   Google Scholar
• Afek, A., J. George, B. Gilburd, et al. 2000. Immunization of low-density lipoprotein receptor deficient (LDL-RD) mice with heat shock protein 65 (HSP-65) promotes early atherosclerosis. J. Autoimmun. 14: 115–121
   PubMed Web of Science ®Google Scholar
• George, J., A. Afek, B. Gilburd, et al. 2001. Cellular and humoral immune responses to heat shock protein 65 are both involved in promoting fatty-streak formation in LDL-receptor deficient mice. J. Am. Coll. Cardiol. 38: 900–905
   PubMedGoogle Scholar
• Foteinos, G., A. R. Afzal, K. Mandal, et al. 2005. Anti-heat shock protein 60 autoantibodies induce atherosclerosis in apolipoprotein E-deficient mice via endothelial damage. Circulation. 112: 1206–1213
   PubMed Web of Science ®Google Scholar
• Klingenberg, R., D. F. Ketelhuth, D. Strodthoff, et al. 2012. Subcutaneous immunization with heat shock protein-65 reduces atherosclerosis in Apoe(−)/(−) mice. Immunobiology 217: 540–547
   PubMed Web of Science ®Google Scholar
• van Puijvelde, G. H., T. van Es, E. J. van Wanrooij, et al. 2007. Induction of oral tolerance to HSP60 or an HSP60-peptide activates T cell regulation and reduces atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 27: 2677–2683
   PubMed Web of Science ®Google Scholar
• Lu, X., D. Chen, V. Endresz, et al. 2010. Immunization with a combination of ApoB and HSP60 epitopes significantly reduces early atherosclerotic lesion in Apobtm2SgyLdlrtm1Her/J mice. Atherosclerosis 212: 472–480
   Google Scholar
• Tsutsumi, A., E. Matsuura, K. Ichikawa, et al. 1996. Antibodies to beta 2-glycoprotein I and clinical manifestations in patients with systemic lupus erythematosus. Arthritis. Rheum. 39: 1466–1474
   PubMedGoogle Scholar
• George, J., B. Afek, M. Gilburd, et al. 1998. Induction of early atherosclerosis in LDL-receptor deficient mice immunized with 2-glycoprotein I. Circulation 98: 1108–1115
   PubMed Web of Science ®Google Scholar
• De Haro, J., L. Esparza, S. Bleda, et al. 2014. Attenuation of early atherosclerotic lesions by immunotolerance with beta2 glycoprotein I and the immunomodulatory effectors interleukin 2 and 10 in a murine model. J. Vasc. Surg. [Epub ahead of print]. doi: 10.1016/j.jvs.2014.05.096
   Google Scholar
• Binder, C. J., S. Horkko, A. Dewan, et al. 2003. Pneumococcal vaccination decreases atherosclerotic lesion formation: molecular mimicry between Streptococcus pneumoniae and oxidized LDL. Nat. Med. 9: 736–743
   PubMed Web of Science ®Google Scholar
• Lu, X., M. Xia, V. Endresz, et al. 2012. Immunization with a combination of 2 peptides derived from the C5a receptor significantly reduces early atherosclerotic lesion in Ldlr(tm1Her) Apob(tm2Sgy) J mice. Arterioscler. Thromb. Vasc. Biol. 32: 2358–2371
   Google Scholar
• Duner, P., F. To, K. Beckmann, et al. 2011. Immunization of apoE−/− mice with aldehyde-modified fibronectin inhibits the development of atherosclerosis. Cardiovasc. Res. 91: 528–536
   PubMed Web of Science ®Google Scholar
• Wigren, M., D. Bengtsson, P. Duner, et al. 2009. Atheroprotective effects of Alum are associated with capture of oxidized LDL antigens and activation of regulatory T cells. Circ. Res. 104: e62–e70
   Google Scholar
• Faria, A. M., and H. L. Weiner. 1999. Oral tolerance: mechanisms and therapeutic applications. Adv. Immunol. 73: 153–264
   PubMed Web of Science ®Google Scholar
• van Puijvelde, G. H., A. D. Hauer, P. de Vos, et al. 2006. Induction of oral tolerance to oxidized low-density lipoprotein ameliorates atherosclerosis. Circulation 114: 1968–1976
   Google Scholar
• Klingenberg, R., M. Lebens, A. Hermansson, et al. 2010. Intranasal immunization with an apolipoprotein B-100 fusion protein induces antigen-specific regulatory T cells and reduces atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 30: 946–952
   PubMed Web of Science ®Google Scholar
• Maron, R., G. Sukhova, A. M. Faria, et al. 2002. Mucosal administration of heat shock protein-65 decreases atherosclerosis and inflammation in aortic arch of low-density lipoprotein receptor-deficient mice. Circulation 106: 1708–1715
   PubMed Web of Science ®Google Scholar
• Xiong, Q., J. Li, L. Jin, et al. 2009. Nasal immunization with heat shock protein 65 attenuates atherosclerosis and reduces serum lipids in cholesterol-fed wild-type rabbits probably through different mechanisms. Immunol. Lett. 125: 40–45
   PubMed Web of Science ®Google Scholar
• Harats, D., N. Yacov, B. Gilburd, et al. 2002. Oral tolerance with heat shock protein 65 attenuates Mycobacterium tuberculosis-induced and high-fat-diet-driven atherosclerotic lesions. J. Am. Coll. Cardiol. 40: 1333–1338
   PubMed Web of Science ®Google Scholar
• Jing, H., L. Yong, L. Haiyan, et al. 2011. Oral administration of Lactococcus lactis delivered heat shock protein 65 attenuates atherosclerosis in low-density lipoprotein receptor-deficient mice. Vaccine 29: 4102–4109
   PubMed Web of Science ®Google Scholar
• Mundkur, L., R. Mukhopadhyay, S. Samson, et al. 2013. Mucosal tolerance to a combination of ApoB and HSP60 peptides controls plaque progression and stabilizes vulnerable plaque in Apob(tm2Sgy)Ldlr(tm1Her)/J mice. PLoS One 8: e58364
   PubMed Web of Science ®Google Scholar